Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert James Glynn, Sc.D., Ph.D.

Co-Author

Back to Details
This page shows the publications co-authored by Robert Glynn and Sebastian Schneeweiss.
Robert Glynn
Connection Strength
16.039
Sebastian Schneeweiss
  1. Schneeweiss S, Glynn RJ. Real-World Data Analytics Fit for Regulatory Decision-Making. Am J Law Med. 2018 May; 44(2-3):197-217.
    View in: PubMed
    Score: 0.858
  2. Glynn RJ, Gagne JJ, Schneeweiss S. Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:138-47.
    View in: PubMed
    Score: 0.566
  3. Schneeweiss S, Patrick AR, Stürmer T, Brookhart MA, Avorn J, Maclure M, Rothman KJ, Glynn RJ. Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care. 2007 Oct; 45(10 Supl 2):S131-42.
    View in: PubMed
    Score: 0.412
  4. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction. Am J Manag Care. 2007 Aug; 13(8):445-52.
    View in: PubMed
    Score: 0.407
  5. Schneeweiss S, Patrick AR, Maclure M, Dormuth CR, Glynn RJ. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: a population-based natural experiment. Circulation. 2007 Apr 24; 115(16):2128-35.
    View in: PubMed
    Score: 0.398
  6. Schneeweiss S, Wang PS, Avorn J, Maclure M, Levin R, Glynn RJ. Consistency of performance ranking of comorbidity adjustment scores in Canadian and U.S. utilization data. J Gen Intern Med. 2004 May; 19(5 Pt 1):444-50.
    View in: PubMed
    Score: 0.325
  7. Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. Clin Pharmacol Ther. 2003 Oct; 74(4):388-400.
    View in: PubMed
    Score: 0.312
  8. Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res. 2003 Aug; 38(4):1103-20.
    View in: PubMed
    Score: 0.309
  9. Schneeweiss S, Maclure M, Soumerai SB, Walker AM, Glynn RJ. Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. J Clin Epidemiol. 2002 Aug; 55(8):833-41.
    View in: PubMed
    Score: 0.288
  10. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol. 2001 Nov 01; 154(9):854-64.
    View in: PubMed
    Score: 0.273
  11. Kim DH, Patorno E, Pawar A, Lee H, Schneeweiss S, Glynn RJ. Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the U.S. Medicare Data. J Gerontol A Biol Sci Med Sci. 2020 May 22; 75(6):1120-1125.
    View in: PubMed
    Score: 0.247
  12. Kim DH, Schneeweiss S, Glynn RJ. Kim et al. Respond to "Estimation With Claims-Based Frailty Indexes". Am J Epidemiol. 2020 05 05; 189(5):373-374.
    View in: PubMed
    Score: 0.246
  13. Spoendlin J, Desai RJ, Franklin JM, Glynn RJ, Payne E, Schneeweiss S. Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis. Clin Pharmacol Ther. 2020 Apr 22.
    View in: PubMed
    Score: 0.246
  14. Franklin JM, Glynn RJ, Suissa S, Schneeweiss S. Emulation Differences vs. Biases When Calibrating Real-World Evidence Findings Against Randomized Controlled Trials. Clin Pharmacol Ther. 2020 Apr; 107(4):735-737.
    View in: PubMed
    Score: 0.243
  15. Lin KJ, Rosenthal GE, Murphy SN, Mandl KD, Jin Y, Glynn RJ, Schneeweiss S. External Validation of an Algorithm to Identify Patients with High Data-Completeness in Electronic Health Records for Comparative Effectiveness Research. Clin Epidemiol. 2020; 12:133-141.
    View in: PubMed
    Score: 0.242
  16. Franklin JM, Pawar A, Martin D, Glynn RJ, Levenson M, Temple R, Schneeweiss S. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. Clin Pharmacol Ther. 2020 Apr; 107(4):817-826.
    View in: PubMed
    Score: 0.238
  17. Glynn RJ, Lunt M, Rothman KJ, Poole C, Schneeweiss S, Stürmer T. Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution. Pharmacoepidemiol Drug Saf. 2019 10; 28(10):1290-1298.
    View in: PubMed
    Score: 0.234
  18. Kim DH, Glynn RJ, Avorn J, Lipsitz LA, Rockwood K, Pawar A, Schneeweiss S. Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study. J Gerontol A Biol Sci Med Sci. 2019 07 12; 74(8):1271-1276.
    View in: PubMed
    Score: 0.233
  19. Franklin JM, Glynn RJ, Martin D, Schneeweiss S. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making. Clin Pharmacol Ther. 2019 04; 105(4):867-877.
    View in: PubMed
    Score: 0.227
  20. Kim DH, Schneeweiss S, Glynn RJ. Comparing Approaches to Measure Frailty in Medicare Data: Deficit-Accumulation Frailty Index Versus Phenotypic Frailty. J Gerontol A Biol Sci Med Sci. 2018 06 14; 73(7):989-990.
    View in: PubMed
    Score: 0.216
  21. Lin KJ, Glynn RJ, Singer DE, Murphy SN, Lii J, Schneeweiss S. Out-of-system Care and Recording of Patient Characteristics Critical for Comparative Effectiveness Research. Epidemiology. 2018 05; 29(3):356-363.
    View in: PubMed
    Score: 0.214
  22. Lin KJ, Singer DE, Glynn RJ, Murphy SN, Lii J, Schneeweiss S. Identifying Patients With High Data Completeness to Improve Validity of Comparative Effectiveness Research in Electronic Health Records Data. Clin Pharmacol Ther. 2018 05; 103(5):899-905.
    View in: PubMed
    Score: 0.206
  23. Lin KJ, Singer DE, Glynn RJ, Blackley S, Zhou L, Liu J, Dube G, Oertel LB, Schneeweiss S. Prediction Score for Anticoagulation Control Quality Among Older Adults. J Am Heart Assoc. 2017 Oct 05; 6(10).
    View in: PubMed
    Score: 0.206
  24. Schneeweiss S, Eddings W, Glynn RJ, Patorno E, Rassen J, Franklin JM. Variable Selection for Confounding Adjustment in High-dimensional Covariate Spaces When Analyzing Healthcare Databases. Epidemiology. 2017 03; 28(2):237-248.
    View in: PubMed
    Score: 0.198
  25. Kumamaru H, Gagne JJ, Glynn RJ, Setoguchi S, Schneeweiss S. Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. J Clin Epidemiol. 2016 08; 76:200-8.
    View in: PubMed
    Score: 0.184
  26. Franklin JM, Eddings W, Glynn RJ, Schneeweiss S. Regularized Regression Versus the High-Dimensional Propensity Score for Confounding Adjustment in Secondary Database Analyses. Am J Epidemiol. 2015 Oct 01; 182(7):651-9.
    View in: PubMed
    Score: 0.177
  27. Franklin JM, Schneeweiss S, Huybrechts KF, Glynn RJ. Evaluating possible confounding by prescriber in comparative effectiveness research. Epidemiology. 2015 Mar; 26(2):238-41.
    View in: PubMed
    Score: 0.172
  28. Kim SC, Solomon DH, Liu J, Franklin JM, Glynn RJ, Schneeweiss S. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs. Am J Med. 2015 May; 128(5):539.e7-17.
    View in: PubMed
    Score: 0.170
  29. Patorno E, Glynn RJ, Hernández-Díaz S, Liu J, Schneeweiss S. Studies with many covariates and few outcomes: selecting covariates and implementing propensity-score-based confounding adjustments. Epidemiology. 2014 Mar; 25(2):268-78.
    View in: PubMed
    Score: 0.161
  30. Patrick AR, Franklin JM, Weinstein MC, Glynn RJ, Schneeweiss S. Sequential value-of-information assessment for prospective drug safety monitoring using claims databases: the comparative safety of prasugrel v. clopidogrel. Med Decis Making. 2013 10; 33(7):949-60.
    View in: PubMed
    Score: 0.154
  31. Patorno E, Glynn RJ, Hernandez-Diaz S, Avorn J, Wahl PM, Bohn RL, Mines D, Liu J, Schneeweiss S. Risk of ischemic cerebrovascular and coronary events in adult users of anticonvulsant medications in routine care settings. J Am Heart Assoc. 2013 Jul 30; 2(4):e000208.
    View in: PubMed
    Score: 0.154
  32. Wang SV, Gagne JJ, Glynn RJ, Schneeweiss S. Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. Epidemiology. 2013 May; 24(3):375-8.
    View in: PubMed
    Score: 0.152
  33. Rassen JA, Shelat AA, Franklin JM, Glynn RJ, Solomon DH, Schneeweiss S. Matching by propensity score in cohort studies with three treatment groups. Epidemiology. 2013 May; 24(3):401-9.
    View in: PubMed
    Score: 0.152
  34. Schneeweiss S, Rassen JA, Glynn RJ, Myers J, Daniel GW, Singer J, Solomon DH, Kim S, Rothman KJ, Liu J, Avorn J. Supplementing claims data with outpatient laboratory test results to improve confounding adjustment in effectiveness studies of lipid-lowering treatments. BMC Med Res Methodol. 2012 Nov 26; 12:180.
    View in: PubMed
    Score: 0.147
  35. Huybrechts KF, Seeger JD, Rothman KJ, Glynn RJ, Avorn J, Schneeweiss S. Bias in comparative effectiveness studies due to regional variation in medical practice intensity: a legitimate concern, or much ado about nothing? Circ Cardiovasc Qual Outcomes. 2012 Sep 01; 5(5):e61-4.
    View in: PubMed
    Score: 0.145
  36. Polinski JM, Shrank WH, Glynn RJ, Huskamp HA, Christopher Roebuck M, Schneeweiss S. Association between the Part D coverage gap and adverse health outcomes. J Am Geriatr Soc. 2012 Aug; 60(8):1408-17.
    View in: PubMed
    Score: 0.143
  37. Gagne JJ, Glynn RJ, Rassen JA, Walker AM, Daniel GW, Sridhar G, Schneeweiss S. Active safety monitoring of newly marketed medications in a distributed data network: application of a semi-automated monitoring system. Clin Pharmacol Ther. 2012 Jul; 92(1):80-6.
    View in: PubMed
    Score: 0.142
  38. Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:69-80.
    View in: PubMed
    Score: 0.141
  39. Polinski JM, Shrank WH, Glynn RJ, Huskamp HA, Roebuck MC, Schneeweiss S. Beneficiaries with cardiovascular disease and thePart D coverage gap. Circ Cardiovasc Qual Outcomes. 2012 May; 5(3):387-95.
    View in: PubMed
    Score: 0.141
  40. Gagne JJ, Rassen JA, Walker AM, Glynn RJ, Schneeweiss S. Active safety monitoring of new medical products using electronic healthcare data: selecting alerting rules. Epidemiology. 2012 Mar; 23(2):238-46.
    View in: PubMed
    Score: 0.140
  41. Polinski JM, Brookhart MA, Glynn RJ, Schneeweiss S. Medicare part D's impact on antipsychotic drug use and costs among elderly patients without prior drug insurance. J Clin Psychopharmacol. 2012 Feb; 32(1):3-10.
    View in: PubMed
    Score: 0.139
  42. Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S. Response to commentary by Marcus and Gibbons. Pharmacoepidemiol Drug Saf. 2012 Jul; 21(7):713.
    View in: PubMed
    Score: 0.139
  43. Gagne JJ, Walker AM, Glynn RJ, Rassen JA, Schneeweiss S. An event-based approach for comparing the performance of methods for prospective medical product monitoring. Pharmacoepidemiol Drug Saf. 2012 Jun; 21(6):631-9.
    View in: PubMed
    Score: 0.138
  44. Rassen JA, Glynn RJ, Rothman KJ, Setoguchi S, Schneeweiss S. Applying propensity scores estimated in a full cohort to adjust for confounding in subgroup analyses. Pharmacoepidemiol Drug Saf. 2012 Jul; 21(7):697-709.
    View in: PubMed
    Score: 0.138
  45. Schneeweiss S, Gagne JJ, Glynn RJ, Ruhl M, Rassen JA. Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development. Clin Pharmacol Ther. 2011 Dec; 90(6):777-90.
    View in: PubMed
    Score: 0.137
  46. Myers JA, Rassen JA, Gagne JJ, Huybrechts KF, Schneeweiss S, Rothman KJ, Joffe MM, Glynn RJ. Effects of adjusting for instrumental variables on bias and precision of effect estimates. Am J Epidemiol. 2011 Dec 01; 174(11):1213-22.
    View in: PubMed
    Score: 0.136
  47. Polinski JM, Shrank WH, Huskamp HA, Glynn RJ, Liberman JN, Schneeweiss S. Changes in drug utilization during a gap in insurance coverage: an examination of the medicare Part D coverage gap. PLoS Med. 2011 Aug; 8(8):e1001075.
    View in: PubMed
    Score: 0.135
  48. Rassen JA, Solomon DH, Glynn RJ, Schneeweiss S. Simultaneously assessing intended and unintended treatment effects of multiple treatment options: a pragmatic "matrix design". Pharmacoepidemiol Drug Saf. 2011 Jul; 20(7):675-83.
    View in: PubMed
    Score: 0.133
  49. Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol. 2011 Jun 15; 173(12):1404-13.
    View in: PubMed
    Score: 0.132
  50. Gagne JJ, Glynn RJ, Avorn J, Levin R, Schneeweiss S. A combined comorbidity score predicted mortality in elderly patients better than existing scores. J Clin Epidemiol. 2011 Jul; 64(7):749-59.
    View in: PubMed
    Score: 0.129
  51. Solomon DH, Rassen JA, Glynn RJ, Lee J, Levin R, Schneeweiss S. The comparative safety of analgesics in older adults with arthritis. Arch Intern Med. 2010 Dec 13; 170(22):1968-76.
    View in: PubMed
    Score: 0.129
  52. Solomon DH, Rassen JA, Glynn RJ, Garneau K, Levin R, Lee J, Schneeweiss S. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med. 2010 Dec 13; 170(22):1979-86.
    View in: PubMed
    Score: 0.129
  53. Brookhart MA, Stürmer T, Glynn RJ, Rassen J, Schneeweiss S. Confounding control in healthcare database research: challenges and potential approaches. Med Care. 2010 Jun; 48(6 Suppl):S114-20.
    View in: PubMed
    Score: 0.124
  54. Schneeweiss S, Glynn RJ, Avorn J, Mamdani M, Mogun H, Solomon DH. NSAID switching and short-term gastrointestinal outcome rates after the withdrawal of rofecoxib. Pharmacoepidemiol Drug Saf. 2009 Dec; 18(12):1134-42.
    View in: PubMed
    Score: 0.120
  55. Rassen JA, Mittleman MA, Glynn RJ, Alan Brookhart M, Schneeweiss S. Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur Heart J. 2010 Mar; 31(5):561-72.
    View in: PubMed
    Score: 0.120
  56. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009 Jul; 20(4):512-22.
    View in: PubMed
    Score: 0.116
  57. Dormuth CR, Neumann P, Maclure M, Glynn RJ, Schneeweiss S. Effects of prescription coinsurance and income-based deductibles on net health plan spending for older users of inhaled medications. Med Care. 2009 May; 47(5):508-16.
    View in: PubMed
    Score: 0.115
  58. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol. 2009 Dec; 62(12):1226-32.
    View in: PubMed
    Score: 0.114
  59. Rassen JA, Brookhart MA, Glynn RJ, Mittleman MA, Schneeweiss S. Instrumental variables II: instrumental variable application-in 25 variations, the physician prescribing preference generally was strong and reduced covariate imbalance. J Clin Epidemiol. 2009 Dec; 62(12):1233-41.
    View in: PubMed
    Score: 0.114
  60. Dormuth CR, Maclure M, Glynn RJ, Neumann P, Brookhart AM, Schneeweiss S. Emergency hospital admissions after income-based deductibles and prescription copayments in older users of inhaled medications. Clin Ther. 2008; 30 Spec No:1038-50.
    View in: PubMed
    Score: 0.105
  61. Stürmer T, Glynn RJ, Rothman KJ, Avorn J, Schneeweiss S. Adjustments for unmeasured confounders in pharmacoepidemiologic database studies using external information. Med Care. 2007 Oct; 45(10 Supl 2):S158-65.
    View in: PubMed
    Score: 0.103
  62. Setoguchi S, Solomon DH, Glynn RJ, Cook EF, Levin R, Schneeweiss S. Agreement of diagnosis and its date for hematologic malignancies and solid tumors between medicare claims and cancer registry data. Cancer Causes Control. 2007 Jun; 18(5):561-9.
    View in: PubMed
    Score: 0.100
  63. Stürmer T, Schneeweiss S, Rothman KJ, Avorn J, Glynn RJ. Performance of propensity score calibration--a simulation study. Am J Epidemiol. 2007 May 15; 165(10):1110-8.
    View in: PubMed
    Score: 0.099
  64. Stürmer T, Schneeweiss S, Rothman KJ, Avorn J, Glynn RJ. Propensity Score Calibration and its Alternatives. Am J Epidemiol. 2007; 165(10):1122-1123.
    View in: PubMed
    Score: 0.098
  65. Stürmer T, Schneeweiss S, Rothman KJ, Avorn J, Glynn RJ. Propensity Score Calibration and its Alternatives. Am J Epidemiol. 2007; 165(10):1122-1123.
    View in: PubMed
    Score: 0.098
  66. Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007 Jan 02; 115(1):27-33.
    View in: PubMed
    Score: 0.097
  67. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, Cook EF, Carney G, Schneeweiss S. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 2006 Sep; 54(9):2757-64.
    View in: PubMed
    Score: 0.096
  68. Dormuth CR, Glynn RJ, Neumann P, Maclure M, Brookhart AM, Schneeweiss S. Impact of two sequential drug cost-sharing policies on the use of inhaled medications in older patients with chronic obstructive pulmonary disease or asthma. Clin Ther. 2006 Jun; 28(6):964-78; discussion 962-3.
    View in: PubMed
    Score: 0.094
  69. Glynn RJ, Schneeweiss S, Wang PS, Levin R, Avorn J. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol. 2006 Aug; 59(8):819-28.
    View in: PubMed
    Score: 0.094
  70. Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006 May; 54(5):1378-89.
    View in: PubMed
    Score: 0.093
  71. Schneeweiss S, Maclure M, Dormuth CR, Glynn RJ, Canning C, Avorn J. A therapeutic substitution policy for proton pump inhibitors: clinical and economic consequences. Clin Pharmacol Ther. 2006 Apr; 79(4):379-88.
    View in: PubMed
    Score: 0.093
  72. Glynn RJ, Schneeweiss S, Stürmer T. Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol. 2006 Mar; 98(3):253-9.
    View in: PubMed
    Score: 0.092
  73. Brookhart MA, Solomon DH, Wang P, Glynn RJ, Avorn J, Schneeweiss S. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. J Clin Epidemiol. 2006 Jan; 59(1):18-25.
    View in: PubMed
    Score: 0.090
  74. Stürmer T, Joshi M, Glynn RJ, Avorn J, Rothman KJ, Schneeweiss S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J Clin Epidemiol. 2006 May; 59(5):437-47.
    View in: PubMed
    Score: 0.090
  75. Avorn J, Schneeweiss S, Sudarsky LR, Benner J, Kiyota Y, Levin R, Glynn RJ. Sudden uncontrollable somnolence and medication use in Parkinson disease. Arch Neurol. 2005 Aug; 62(8):1242-8.
    View in: PubMed
    Score: 0.089
  76. Stürmer T, Schneeweiss S, Avorn J, Glynn RJ. Adjusting effect estimates for unmeasured confounding with validation data using propensity score calibration. Am J Epidemiol. 2005 Aug 01; 162(3):279-89.
    View in: PubMed
    Score: 0.088
  77. Wang PS, Avorn J, Brookhart MA, Mogun H, Schneeweiss S, Fischer MA, Glynn RJ. Effects of noncardiovascular comorbidities on antihypertensive use in elderly hypertensives. Hypertension. 2005 Aug; 46(2):273-9.
    View in: PubMed
    Score: 0.088
  78. Stürmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol. 2005 May 01; 161(9):891-8.
    View in: PubMed
    Score: 0.087
  79. Schneeweiss S, Glynn RJ, Tsai EH, Avorn J, Solomon DH. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitors and myocardial infarction. Epidemiology. 2005 Jan; 16(1):17-24.
    View in: PubMed
    Score: 0.085
  80. Schneeweiss S, Glynn RJ, Avorn J, Solomon DH. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol. 2005 Jan; 58(1):98-102.
    View in: PubMed
    Score: 0.085
  81. Schneeweiss S, Maclure M, Carleton B, Glynn RJ, Avorn J. Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational evaluations. BMJ. 2004 Mar 06; 328(7439):560.
    View in: PubMed
    Score: 0.080
  82. Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, Walker AM. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. CMAJ. 2002 Mar 19; 166(6):737-45.
    View in: PubMed
    Score: 0.070
  83. Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N Engl J Med. 2002 Mar 14; 346(11):822-9.
    View in: PubMed
    Score: 0.070
  84. Lee MP, Glynn RJ, Schneeweiss S, Lin KJ, Patorno E, Barberio J, Levin R, Evers T, Wang SV, Desai RJ. Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model. Clin Epidemiol. 2020; 12:607-616.
    View in: PubMed
    Score: 0.062
  85. Connolly JG, Glynn RJ, Schneeweiss S, Gagne JJ. Improving measurement of binary covariates in claims data: A simulation study. Pharmacoepidemiol Drug Saf. 2020 Jan 23.
    View in: PubMed
    Score: 0.060
  86. Connolly JG, Schneeweiss S, Glynn RJ, Gagne JJ. Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. Drug Saf. 2019 11; 42(11):1355-1363.
    View in: PubMed
    Score: 0.059
  87. Bohn J, Schneeweiss S, Glynn RJ, Toh S, Wyss R, Desai R, Gagne JJ. Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches. EGEMS (Wash DC). 2019 Jul 15; 7(1):27.
    View in: PubMed
    Score: 0.058
  88. Bykov K, Schneeweiss S, Glynn RJ, Mittleman MA, Gagne JJ. A Case-Crossover-Based Screening Approach to Identifying Clinically Relevant Drug-Drug Interactions in Electronic Healthcare Data. Clin Pharmacol Ther. 2019 07; 106(1):238-244.
    View in: PubMed
    Score: 0.057
  89. Bykov K, Mittleman MA, Glynn RJ, Schneeweiss S, Gagne JJ. The Case-Crossover Design for Drug-Drug Interactions: Considerations for Implementation. Epidemiology. 2019 03; 30(2):204-211.
    View in: PubMed
    Score: 0.057
  90. Connolly JG, Schneeweiss S, Glynn RJ, Gagne JJ. Quantifying bias reduction with fixed-duration versus all-available covariate assessment periods. Pharmacoepidemiol Drug Saf. 2019 05; 28(5):665-670.
    View in: PubMed
    Score: 0.057
  91. Krumme AA, Glynn RJ, Schneeweiss S, Choudhry NK, Tong AY, Gagne JJ. Defining Exposure in Observational Studies Comparing Outcomes of Treatment Discontinuation. Circ Cardiovasc Qual Outcomes. 2018 07; 11(7):e004684.
    View in: PubMed
    Score: 0.054
  92. Kim DH, Schneeweiss S, Glynn RJ, Lipsitz LA, Rockwood K, Avorn J. Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index. J Gerontol A Biol Sci Med Sci. 2018 06 14; 73(7):980-987.
    View in: PubMed
    Score: 0.054
  93. Wang SV, Kulldorff M, Glynn RJ, Gagne JJ, Pottegård A, Rothman KJ, Schneeweiss S, Walker AM. Reuse of data sources to evaluate drug safety signals: When is it appropriate? Pharmacoepidemiol Drug Saf. 2018 06; 27(6):567-569.
    View in: PubMed
    Score: 0.054
  94. Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC. Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ. 2018 02 06; 360:k119.
    View in: PubMed
    Score: 0.053
  95. Wang SV, Huybrechts KF, Fischer MA, Franklin JM, Glynn RJ, Schneeweiss S, Gagne JJ. Generalized boosted modeling to identify subgroups where effect of dabigatran versus warfarin may differ: An observational cohort study of patients with atrial fibrillation. Pharmacoepidemiol Drug Saf. 2018 04; 27(4):383-390.
    View in: PubMed
    Score: 0.053
  96. Krumme AA, Glynn RJ, Schneeweiss S, Gagne JJ, Dougherty JS, Brill G, Choudhry NK. Medication Synchronization Programs Improve Adherence To Cardiovascular Medications And Health Care Use. Health Aff (Millwood). 2018 01; 37(1):125-133.
    View in: PubMed
    Score: 0.052
  97. Krumme AA, Pawar A, Schneeweiss S, Glynn RJ, Choudhry NK, Kulldorff M, Ortiz AS, Avorn J, Gagne JJ. Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. J Comp Eff Res. 2018 01; 7(1):57-66.
    View in: PubMed
    Score: 0.052
  98. Bykov K, Schneeweiss S, Glynn RJ, Mittleman MA, Bates DW, Gagne JJ. Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis. Drug Saf. 2017 10; 40(10):923-932.
    View in: PubMed
    Score: 0.051
  99. Wang SV, Franklin JM, Glynn RJ, Schneeweiss S, Eddings W, Gagne JJ. Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ. 2016 May 24; 353:i2607.
    View in: PubMed
    Score: 0.047
  100. Kumamaru H, Schneeweiss S, Glynn RJ, Setoguchi S, Gagne JJ. Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data. Emerg Themes Epidemiol. 2016; 13:5.
    View in: PubMed
    Score: 0.046
  101. Wangge G, Schneeweiss S, Glynn RJ, Gagne JJ. Developing alerting thresholds for prospective drug safety monitoring. Pharmacoepidemiol Drug Saf. 2016 07; 25(7):755-62.
    View in: PubMed
    Score: 0.045
  102. Kim SC, Schneeweiss S, Choudhry N, Liu J, Glynn RJ, Solomon DH. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study. Am J Med. 2015 Jun; 128(6):653.e7-653.e16.
    View in: PubMed
    Score: 0.043
  103. Kim SC, Schneeweiss S, Glynn RJ, Doherty M, Goldfine AB, Solomon DH. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Ann Rheum Dis. 2015 Nov; 74(11):1968-75.
    View in: PubMed
    Score: 0.041
  104. Kim SC, Glynn RJ, Giovannucci E, Hernández-Díaz S, Liu J, Feldman S, Karlson EW, Schneeweiss S, Solomon DH. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. 2015 Jul; 74(7):1360-7.
    View in: PubMed
    Score: 0.040
  105. Polinski JM, Shrank WH, Glynn RJ, Schneeweiss S, Huskamp HA, Roebuck MC. Response letter to Eltonsy and colleagues. J Am Geriatr Soc. 2013 May; 61(5):848-9.
    View in: PubMed
    Score: 0.038
  106. Polinski JM, Schneeweiss S, Glynn RJ, Lii J, Rassen JA. Confronting "confounding by health system use" in Medicare Part D: comparative effectiveness of propensity score approaches to confounding adjustment. Pharmacoepidemiol Drug Saf. 2012 May; 21 Suppl 2:90-8.
    View in: PubMed
    Score: 0.035
  107. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, Reisman L, Fernandes J, Spettell C, Lee JL, Levin R, Brennan T, Shrank WH. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011 Dec 01; 365(22):2088-97.
    View in: PubMed
    Score: 0.034
  108. Patrick AR, Schneeweiss S, Brookhart MA, Glynn RJ, Rothman KJ, Avorn J, Stürmer T. The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf. 2011 Jun; 20(6):551-9.
    View in: PubMed
    Score: 0.033
  109. Shrank WH, Choudhry NK, Solomon DH, Snedden TM, Lee TH, Glynn RJ, Brown TV, Jolda C, Spetman M, Brookhart MA, Schneeweiss S, Avorn J. Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial. Am Heart J. 2009 Apr; 157(4):613-9.
    View in: PubMed
    Score: 0.028
  110. Rassen JA, Schneeweiss S, Glynn RJ, Mittleman MA, Brookhart MA. Instrumental variable analysis for estimation of treatment effects with dichotomous outcomes. Am J Epidemiol. 2009 Feb 01; 169(3):273-84.
    View in: PubMed
    Score: 0.028
  111. Solomon DH, Glynn RJ, Rothman KJ, Schneeweiss S, Setoguchi S, Mogun H, Avorn J, Stürmer T. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008 Aug 15; 59(8):1097-104.
    View in: PubMed
    Score: 0.027
  112. Choudhry NK, Brennan T, Toscano M, Spettell C, Glynn RJ, Rubino M, Schneeweiss S, Brookhart AM, Fernandes J, Mathew S, Christiansen B, Antman EM, Avorn J, Shrank WH. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies. Am Heart J. 2008 Jul; 156(1):31-6.
    View in: PubMed
    Score: 0.027
  113. Setoguchi S, Schneeweiss S, Brookhart MA, Glynn RJ, Cook EF. Evaluating uses of data mining techniques in propensity score estimation: a simulation study. Pharmacoepidemiol Drug Saf. 2008 Jun; 17(6):546-55.
    View in: PubMed
    Score: 0.027
  114. Winkelmayer WC, Benner JS, Glynn RJ, Schneeweiss S, Wang PS, Brookhart MA, Levin R, Jackson JD, Avorn J. Assessing health state utilities in elderly patients at cardiovascular risk. Med Decis Making. 2006 May-Jun; 26(3):247-54.
    View in: PubMed
    Score: 0.023
  115. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Am J Epidemiol. 2006 Jun 15; 163(12):1149-56.
    View in: PubMed
    Score: 0.023
  116. Perlis RH, Ganz DA, Avorn J, Schneeweiss S, Glynn RJ, Smoller JW, Wang PS. Pharmacogenetic testing in the clinical management of schizophrenia: a decision-analytic model. J Clin Psychopharmacol. 2005 Oct; 25(5):427-34.
    View in: PubMed
    Score: 0.022
  117. Wang PS, Schneeweiss S, Brookhart MA, Glynn RJ, Mogun H, Patrick AR, Avorn J. Suboptimal antidepressant use in the elderly. J Clin Psychopharmacol. 2005 Apr; 25(2):118-26.
    View in: PubMed
    Score: 0.022
  118. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J. 2004 Jul; 148(1):99-104.
    View in: PubMed
    Score: 0.021
  119. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004 May 04; 109(17):2068-73.
    View in: PubMed
    Score: 0.020
  120. Wang PS, Schneeweiss S, Glynn RJ, Mogun H, Avorn J. Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Ann Epidemiol. 2004 Apr; 14(4):296-303.
    View in: PubMed
    Score: 0.020
  121. Solomon DH, Schneeweiss S, Glynn RJ, Levin R, Avorn J. Determinants of selective cyclooxygenase-2 inhibitor prescribing: are patient or physician characteristics more important? Am J Med. 2003 Dec 15; 115(9):715-20.
    View in: PubMed
    Score: 0.020
  122. Duetz MS, Schneeweiss S, Maclure M, Abel T, Glynn RJ, Soumerai SB. Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia. Clin Ther. 2003 Jan; 25(1):273-84.
    View in: PubMed
    Score: 0.019
  123. Avorn J, Benner J, Ford I, Ganz DA, Gaw A, Glynn RJ, Jackson J, Lagaay AM, Schneeweiss S, Walley T, Wang PS. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial. Control Clin Trials. 2002 Dec; 23(6):757-73.
    View in: PubMed
    Score: 0.018
  124. Wang PS, Glynn RJ, Ganz DA, Schneeweiss S, Levin R, Avorn J. Clozapine use and risk of diabetes mellitus. J Clin Psychopharmacol. 2002 Jun; 22(3):236-43.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2020 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.